A 10-valent pneumococcal conjugate vaccine (PCV) is effective in reducing the number of new cases of likely-bacterial community-acquired pneumonia in infants in Latin America, according to a study published in this week's PLOS Medicine. Xavier Sáez-Llorens and colleagues from Department of Infectious Diseases, Panama found that the 10-valent PCV reduced the number of new cases of likely-bacterial community-acquired pneumonia in infants by 22% (95% CI: 7.7, 34.2) compared to those who received the control vaccine in the per-protocol cohort at the pre-planned interim analysis (average follow-up of 23 months), which was the primary outcome of the study.
The researchers reached these conclusions by performing a double-blind randomized controlled trial (the Clinical Otitis Media and Pneumonia Study; COMPAS) that enrolled around 23,821 infants living in urban areas of Argentina, Panama, and Colombia. Half of the infants were randomly assigned to receive the 10-valent PCV at 2, 4, and 6 months of age and a booster dose at age 15–18 months, with the remaining half receiving a hepatitis control vaccine at the same intervals. At the end of the study (average follow up 30 months), the number of new cases of likely-bacterial community-acquired pneumonia was 18.2% (95% CI: 4.1%, 30.3%) lower in the per-protocol analysis in those receiving the 10-valent PCV compared to those receiving the control vaccine. The vaccine also led to a 16.1% (95% CI: -1.1%, 30.4%; one-sided p = 0.032) reduction in confirmed acute otitis media, a 67.1% (95% CI: 17.0%, 86.9%) reduction in vaccine serotype acute otitis media, a 65% (95% CI: 11.1%, 86.2%) reduction in any invasive pneumococcal disease, and a 100% (95% CI: 74.3%, 100%) reduction in vaccine serotype invasive pneumococcal disease. Serious adverse events were reported in about one-fifth of children, with a similar number of reports in those receiving the PCV and control vaccine, and were not thought to be attributable to the PCV.
The robustness of these findings may be limited by the withdrawal of 14% of participants from the trial mostly because of adverse media coverage in 2007/2008 due to unfounded rumors of a causal relationship between the vaccine and infant mortality, and by the low number of reported cases of acute otitis media. However, these findings show that this vaccine is efficacious against pneumococcal diseases that often affect young children in Latin America.
The authors say: "Now, children of Latin America and elsewhere in the world can benefit from a vaccine that has demonstrated efficacy against a variety of pneumococcal infections associated with substantial morbidity and mortality".
Explore further: Researchers find ear infections down, thanks to vaccine
More information: Tregnaghi MW, Sa´ez-Llorens X, Lo´pez P, Abate H, Smith E, et al. (2014) Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med 11(6): e1001657. DOI: 10.1371/journal.pmed.1001657
Medical Xpress on facebook
Related Stories
Reduced-dose schedule for pneumococcal vaccine in infants shows effectiveness
Jul 07, 2009
Infants who received two or three primary doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) both had a decreased rate of carrying pneumococcal microorganisms that can cause pneumonia and other infections, compared ...
Researchers find ear infections down, thanks to vaccine
Nov 25, 2013
Otitis media, more commonly known as ear infection, is the leading cause of pediatric health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Researchers from the University ...
Vaccine against pneumococcal infections has led to widespread reduction in serious disease
Sep 24, 2013
Vaccination with the pneumococcal conjugate vaccine-7 [PCV7—a vaccine that covers 7 strains (serotypes) of Streptococcus pneumoniae] is linked to overall decreases in the rate of serious infections caused by this bacterium, ...
Comparison of antibody levels for four different immunization schedules for PCVs
Sep 03, 2013
The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster ...
First European randomized trial confirms new pneumococcal vaccine highly effective in infants
Nov 15, 2012
A new conjugate vaccine is highly effective (93%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most ...
Recommended for you
Researchers shut down a SARS cloaking system: Findings could lead to SARS, MERS vaccines
6 minutes ago
A Purdue University-led research team has figured out how to disable a part of the SARS virus responsible for hiding it from the immune system; a critical step in developing a vaccine against the deadly disease.
Cholera outbreak spreads in South Sudan
59 minutes ago
An outbreak of cholera has spread outside of war-torn South Sudan's capital Juba for the first time since the deadly disease appeared last month, health officials said Tuesday.
High risk of recurrence of two life-threatening adverse drug reactions
1 hour ago
Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a study in the June 4 issue of JAMA.
Food handlers cause most food-poisoning cases
1 hour ago
(HealthDay)—Norovirus, the so-called "cruise ship virus," is more often caused by infected restaurant workers than outbreaks on the high seas, U.S. health officials said Tuesday.
Saudi MERS toll surges to 282: ministry
1 hour ago
Saudi Arabia's death toll from the MERS coronavirus has surged to 282, the health ministry said on Tuesday, following recalculations in the world's worst hit country.
Saudi review finds over 100 more MERS infections
3 hours ago
Saudi Arabia, which is grappling to contain the spread of a frequently deadly respiratory virus, announced Tuesday that a review of the illness led authorities to sharply revise upward the number of confirmed ...
User comments
© Medical Xpress 2011-2014, Science X network
A 10-valent pneumococcal conjugate vaccine (PCV) is effective in reducing the number of new cases of likely-bacterial community-acquired pneumonia in infants in Latin America, according to a study published in this week's PLOS Medicine. Xavier Sáez-Llorens and colleagues from Department of Infectious Diseases, Panama found that the 10-valent PCV reduced the number of new cases of likely-bacterial community-acquired pneumonia in infants by 22% (95% CI: 7.7, 34.2) compared to those who received the control vaccine in the per-protocol cohort at the pre-planned interim analysis (average follow-up of 23 months), which was the primary outcome of the study.
The researchers reached these conclusions by performing a double-blind randomized controlled trial (the Clinical Otitis Media and Pneumonia Study; COMPAS) that enrolled around 23,821 infants living in urban areas of Argentina, Panama, and Colombia. Half of the infants were randomly assigned to receive the 10-valent PCV at 2, 4, and 6 months of age and a booster dose at age 15–18 months, with the remaining half receiving a hepatitis control vaccine at the same intervals. At the end of the study (average follow up 30 months), the number of new cases of likely-bacterial community-acquired pneumonia was 18.2% (95% CI: 4.1%, 30.3%) lower in the per-protocol analysis in those receiving the 10-valent PCV compared to those receiving the control vaccine. The vaccine also led to a 16.1% (95% CI: -1.1%, 30.4%; one-sided p = 0.032) reduction in confirmed acute otitis media, a 67.1% (95% CI: 17.0%, 86.9%) reduction in vaccine serotype acute otitis media, a 65% (95% CI: 11.1%, 86.2%) reduction in any invasive pneumococcal disease, and a 100% (95% CI: 74.3%, 100%) reduction in vaccine serotype invasive pneumococcal disease. Serious adverse events were reported in about one-fifth of children, with a similar number of reports in those receiving the PCV and control vaccine, and were not thought to be attributable to the PCV.
The robustness of these findings may be limited by the withdrawal of 14% of participants from the trial mostly because of adverse media coverage in 2007/2008 due to unfounded rumors of a causal relationship between the vaccine and infant mortality, and by the low number of reported cases of acute otitis media. However, these findings show that this vaccine is efficacious against pneumococcal diseases that often affect young children in Latin America.
The authors say: "Now, children of Latin America and elsewhere in the world can benefit from a vaccine that has demonstrated efficacy against a variety of pneumococcal infections associated with substantial morbidity and mortality".
Explore further: Researchers find ear infections down, thanks to vaccine
More information: Tregnaghi MW, Sa´ez-Llorens X, Lo´pez P, Abate H, Smith E, et al. (2014) Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med 11(6): e1001657. DOI: 10.1371/journal.pmed.1001657
Medical Xpress on facebook
Related Stories
Reduced-dose schedule for pneumococcal vaccine in infants shows effectiveness
Jul 07, 2009
Infants who received two or three primary doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) both had a decreased rate of carrying pneumococcal microorganisms that can cause pneumonia and other infections, compared ...
Researchers find ear infections down, thanks to vaccine
Nov 25, 2013
Otitis media, more commonly known as ear infection, is the leading cause of pediatric health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Researchers from the University ...
Vaccine against pneumococcal infections has led to widespread reduction in serious disease
Sep 24, 2013
Vaccination with the pneumococcal conjugate vaccine-7 [PCV7—a vaccine that covers 7 strains (serotypes) of Streptococcus pneumoniae] is linked to overall decreases in the rate of serious infections caused by this bacterium, ...
Comparison of antibody levels for four different immunization schedules for PCVs
Sep 03, 2013
The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster ...
First European randomized trial confirms new pneumococcal vaccine highly effective in infants
Nov 15, 2012
A new conjugate vaccine is highly effective (93%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most ...
Recommended for you
Researchers shut down a SARS cloaking system: Findings could lead to SARS, MERS vaccines
6 minutes ago
A Purdue University-led research team has figured out how to disable a part of the SARS virus responsible for hiding it from the immune system; a critical step in developing a vaccine against the deadly disease.
Cholera outbreak spreads in South Sudan
59 minutes ago
An outbreak of cholera has spread outside of war-torn South Sudan's capital Juba for the first time since the deadly disease appeared last month, health officials said Tuesday.
High risk of recurrence of two life-threatening adverse drug reactions
1 hour ago
Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a study in the June 4 issue of JAMA.
Food handlers cause most food-poisoning cases
1 hour ago
(HealthDay)—Norovirus, the so-called "cruise ship virus," is more often caused by infected restaurant workers than outbreaks on the high seas, U.S. health officials said Tuesday.
Saudi MERS toll surges to 282: ministry
1 hour ago
Saudi Arabia's death toll from the MERS coronavirus has surged to 282, the health ministry said on Tuesday, following recalculations in the world's worst hit country.
Saudi review finds over 100 more MERS infections
3 hours ago
Saudi Arabia, which is grappling to contain the spread of a frequently deadly respiratory virus, announced Tuesday that a review of the illness led authorities to sharply revise upward the number of confirmed ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment